Peptides: The Science, Uses & Safety | Dr. Abud Bakri

Bakri describes tearing his triceps while lifting with stronger partners, resulting in extensive ecchymosis. He self-administered BPC-157 locally (injecting into the belly of the muscle) along with other peptides, and his physical therapist remarked on unprecedented healing speed; he regained full function in 3-4 weeks instead of the expected 3 months. He suspects that the commonly cited microgram doses are insufficient for humans, because they derive from mouse studies without allometric scaling. He acknowledges that he would have likely healed without intervention but that the accelerated timeline was impressive. This anecdote encapsulates both the promise and the peril: the effect size is tantalizing but rests on a single N-of-1, unblinded experience.

Bakri observed that many patients with early-onset cancers or poor COVID outcomes had lymphocyte counts that were low-normal or borderline low, but no one was paying attention. He dug into the literature and found that the lymphocyte-to-monocyte ratio consistently predicts outcomes across a startling range of diseases. He has been lobbying hospital colleagues to adopt this cheap, universally available metric, but clinical inertia has prevented uptake. He suggests that peptide interventions (thymosin alpha-1, thymic extracts) could be monitored by tracking this ratio, with the goal of pushing it from, say, 2:1 to 5:1 or higher. This provides a pragmatic, evidence-informed endpoint for immune optimization.

Bakri explains that receptor status dictates everything from regulatory pathways to expected side-effect profiles. For example, GLP-1 agonists like semaglutide and tirzepatide are robustly studied, have established LD50s, and benefit from clear patent protections. In contrast, BPC-157—lacking an identified receptor—has no known LD50 in animals, making it impossible to define a safe dosing ceiling for humans. He notes that some Russian peptides (e.g., epitalon, pinealon) appear to act as epigenetic modifiers, binding to DNA grooves and altering chromatin accessibility, much like steroid hormones but without a classical receptor. This classification explains why some compounds generate spectacular anecdotes (e.g., rapid tendon healing) but fail to accumulate the kind of standardized evidence required for FDA approval. The lack of a receptor also complicates patent and compounding laws, as manufacturers can tweak a single amino acid to create a 'new' compound, undermining investment in formal trials.

Bakri details that Pavlov sold canine gastric juices as a medicinal elixir in the early 1900s, and Selye observed that stressed animals developed gastric ulcers, adrenal enlargement, and thymic atrophy. In 1991, the Croatian team isolated a large 40,000-dalton protein (BPC) and then the 15-amino-acid BPC-157, demonstrating that it could prevent ulcers, accelerate tendon healing, and even block alcohol withdrawal in rodents. The tendon paper became a bodybuilding meme, but Bakri argues that the gut-brain axis effects (e.g., reducing the intoxicating and reinforcing effects of alcohol) are far more intriguing. He points to two small human trials using rectal BPC enemas for ulcerative colitis (up to 80 mg) that showed a positive signal with no systemic absorption, suggesting the peptide acts locally. This re-centers the debate on GI and addiction indications, which may be easier to trial than MSK injuries.

Bakri explains that during the semaglutide/tirzepatide shortages, the FDA actually encouraged compounders to produce GLP-1s, which led to enormous profits and a business model that quickly expanded to other peptides. When BPC-157 was placed on the Category 2 list, compounders rebranded it as pentadecapeptide arginate (PDA), claiming it is a distinct entity. Now that Category 2 status has been revoked but Category 1 status not granted, physicians must navigate conflicting signals: the FDA may tacitly allow compounding, but state medical boards may threaten licensure. Bakri received a letter from one state warning him not to prescribe non-FDA-approved peptides. This patchwork forces patients toward unregulated research-grade vendors, undermining safety. He predicts a surge in telemedicine platforms offering 'checkout-style' peptide prescriptions with minimal oversight.

Bakri describes the stack as the logical extension of bodybuilding pharmacology into the mainstream weight-loss and anti-aging markets. The GLP-1 component (especially the triple-agonist retatrutide) can produce 20-30% body weight loss, while GH secretagogues like tesamorelin restore IGF-1 to youthful levels, improving skin, sleep, and recovery. The androgen piece maintains or builds muscle mass during caloric deficit. However, he warns that the combination may exacerbate insulin resistance (GH effect), accelerate prostate growth, and potentiate tumor growth if subclinical malignancies are present. He also notes that the popularity of this stack is driving a black market for raw peptides, with China as the primary API source, and that the 'healthy' appearance may mask future adverse outcomes.

Bakri emphasizes that thymic involution is not merely an anatomical curiosity but a functional driver of immunosenescence. The thymus produces naïve T cells that are trained to distinguish self from non-self; as output declines after age 30, the immune system becomes increasingly reliant on memory cells, leading to higher rates of autoimmunity, cancer, and infections. He proposes that a '$3 lab test' — the lymphocyte-to-monocyte ratio on a standard complete blood count — serves as a real-world proxy for immune resilience, with scores below 1.0 associated with worse outcomes in nearly every chronic disease. This metric, he argues, could be used to evaluate peptide interventions such as thymosin alpha-1. Bakri also notes that Soviet researcher Vladimir Khavinson showed that a 10-day annual course of pineal/thymus peptides over 15 years reduced all-cause mortality in nursing home residents, providing albeit low-quality human evidence that thymic support may extend healthspan.